Meeting
2018 ASCO Annual Meeting
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
Authors
Jonathan R. Strosberg
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Jonathan R. Strosberg , Edward M. Wolin , Beth A. Chasen , Matthew H. Kulke , David L Bushnell Jr., Martyn E. Caplin , Richard P. Baum , Timothy J. Hobday , Andrew Eugene Hendifar , Maribel Lopera Sierra , Kjell E. Oberg , Philippe B. Ruszniewski , Eric Krenning
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Clinical Trial Registration Number
NCT01578239
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4099)
DOI
10.1200/JCO.2018.36.15_suppl.4099
Abstract #
4099
Poster Bd #
288
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.
First Author: Jonathan R. Strosberg
Poster
2019 ASCO Annual Meeting
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg
Poster
2017 Gastrointestinal Cancers Symposium
Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.
First Author: Jonathan R. Strosberg
Poster
2021 ASCO Annual Meeting
Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg